Department of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumor IRCCS "Fondazione G. Pascale", Naples, Italy.
Experimental Clinical Abdominal Oncology Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy.
J Transl Med. 2023 Jul 20;21(1):488. doi: 10.1186/s12967-023-04329-7.
The discovery and development of novel treatments that harness the patient's immune system and prevent immune escape has dramatically improved outcomes for patients across cancer types. However, not all patients respond to immunotherapy, acquired resistance remains a challenge, and responses are poor in certain tumors which are considered to be immunologically cold. This has led to the need for new immunotherapy-based approaches, including adoptive cell transfer (ACT), therapeutic vaccines, and novel immune checkpoint inhibitors. These new approaches are focused on patients with an inadequate response to current treatments, with emerging evidence of improved responses in various cancers with new immunotherapy agents, often in combinations with existing agents. The use of cell therapies, drivers of immune response, and trends in immunotherapy were the focus of the Immunotherapy Bridge (November 30th-December 1st, 2022), organized by the Fondazione Melanoma Onlus, Naples, Italy, in collaboration with the Society for Immunotherapy of Cancer.
新型治疗方法的发现和发展利用了患者的免疫系统并防止免疫逃逸，这极大地改善了多种癌症类型患者的预后。然而，并非所有患者都对免疫疗法有反应，获得性耐药仍然是一个挑战，某些被认为免疫冷的肿瘤的反应较差。这导致需要新的基于免疫疗法的方法，包括过继细胞转移（ACT）、治疗性疫苗和新型免疫检查点抑制剂。这些新方法专注于对当前治疗反应不足的患者，新的免疫治疗药物在各种癌症中的反应得到改善的证据不断涌现，通常与现有药物联合使用。细胞疗法的应用、免疫反应的驱动因素和免疫疗法的趋势是意大利那不勒斯 Melanoma Onlus 基金会与癌症免疫治疗学会合作组织的免疫治疗桥会议（2022 年 11 月 30 日至 12 月 1 日）的重点。
